Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males

International Journal of Impotence Research volume 21, pages 1–8 (2009)Cite this article

Abstract

The new ISA, ISSAM, EAU, EAA and ASA recommendations on the investigation, treatment and monitoring of late-onset hypogonadism in males provide updated evidence-based information for clinicians who diagnose and treat patients with adult onset, age related testosterone deficiency.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Araujo AB, Esche GR, Kupelian V, O’donnell AB, Travison TG, Williams RE et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007; 92: 4241–4247.

    Article  CAS  PubMed  Google Scholar 

  2. Gray A, Feldman HA, McKinlay JB, Longcope C . Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991; 73: 1016–1025.

    Article  CAS  PubMed  Google Scholar 

  3. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR . Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metabol 2001; 86: 724–731.

    Article  CAS  Google Scholar 

  4. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008; 93: 2737–2745.

    Article  CAS  PubMed  Google Scholar 

  5. Liverman CT, Blazer DG . Testosterone and Aging: Clinical Research Directions. National Academies Press: Washington, DC, 2004.

    Google Scholar 

  6. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 381–394.

    Article  CAS  Google Scholar 

  7. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 280–293.

    Article  CAS  Google Scholar 

  8. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89: 503–510.

    Article  CAS  PubMed  Google Scholar 

  9. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005; 90: 1502–1510.

    Article  CAS  PubMed  Google Scholar 

  10. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 2647–2653.

    CAS  PubMed  Google Scholar 

  11. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 1966–1972.

    CAS  PubMed  Google Scholar 

  12. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995–2010.

    Article  CAS  PubMed  Google Scholar 

  13. The Practice Committee of the American Society for Reproductive Medicine. Treatment of androgen deficiency in the aging male. Fertil Steril 2004; 81: 1437–1440.

    Article  Google Scholar 

  14. AACE Hypogonadism Task Force. American Association of Clinical Endocrinologist Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients-Update 2002; http://www.aace.com/pub/pdf/guidelines/hypogonadism.pdf 2002.

  15. Morales A, Lunenfeld B . Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male 2002; 5: 74–86.

    Article  CAS  PubMed  Google Scholar 

  16. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ et al. Investigation, treatment and monitoring of late-onset hypogonadism in males ISA, ISSAM, and EAU recommendations. Eur Urol 2005; 48: 1–4.

    Article  CAS  PubMed  Google Scholar 

  17. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2005; 8: 56–58.

    Article  CAS  PubMed  Google Scholar 

  18. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 2005; 28: 125–127.

    Article  CAS  PubMed  Google Scholar 

  19. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl 2006; 27: 135–137.

    Article  CAS  PubMed  Google Scholar 

  20. Morales A, Schulman CC, Tostain J, Wu CW . Testosterone deficiency syndrome (TDS) needs to be named appropriately—the importance of accurate terminology. Eur Urol 2006; 50: 407–409.

    Article  PubMed  Google Scholar 

  21. Schiavi RC, Schreiner-Engel P, White D, Mandeli J . The relationship between pituitary-gonadal function and sexual behavior in healthy aging men. Psychosom Med 1991; 53: 363–374.

    Article  CAS  PubMed  Google Scholar 

  22. Travison TG, Morley JE, Araujo AB, O’donnell AB, McKinlay JB . The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab 2006; 91: 2509–2513.

    Article  CAS  PubMed  Google Scholar 

  23. Kelleher S, Conway AJ, Handelsman DJ . Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004; 89: 3813–3817.

    Article  CAS  PubMed  Google Scholar 

  24. Morales A, Spevack M, Emerson L, Kuzmarov I, Casey R, Black A et al. Adding to the controversy: pitfalls in the diagnosis of testosterone deficiency syndromes with questionnaires and biochemistry. Aging Male 2007; 10: 57–65.

    Article  CAS  PubMed  Google Scholar 

  25. Zitzmann M, Faber S, Nieschlag E . Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006; 91: 4335–4343.

    Article  CAS  PubMed  Google Scholar 

  26. Heinemann LA, Saad F, Heinemann K, Thai DM . Can results of the Aging Males’ Symptoms (AMS) scale predict those of screening scales for androgen deficiency? Aging Male 2004; 7: 211–218.

    Article  CAS  PubMed  Google Scholar 

  27. Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad F, Thai DM . The Aging Males’ Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004; 46: 80–87.

    Article  PubMed  Google Scholar 

  28. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239–1242.

    Article  CAS  PubMed  Google Scholar 

  29. Tancredi A, Reginster JY, Schleich F, Pire G, Maassen P, Luyckx F et al. Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. Eur J Endocrinol 2004; 151: 355–360.

    Article  CAS  PubMed  Google Scholar 

  30. Beutel ME, Wiltink J, Hauck EW, Auch D, Behre HM, Brahler E et al. Correlations between hormones, physical, and affective parameters in aging urologic outpatients. Eur Urol 2005; 47: 749–755.

    Article  CAS  PubMed  Google Scholar 

  31. Diver MJ, Imtiaz KE, Ahmad AM, Vora JP, Fraser WD . Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf) 2003; 58: 710–717.

    Article  CAS  Google Scholar 

  32. Citron JT, Ettinger B, Rubinoff H, Ettinger VM, Minkoff J, Hom F et al. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. J Urol 1996; 155: 529–533.

    Article  CAS  PubMed  Google Scholar 

  33. Bunch TJ, Abraham D, Wang S, Meikle AW . Pituitary radiographic abnormalities and clinical correlates of hypogonadism in elderly males presenting with erectile dysfunction. Aging Male 2002; 5: 38–46.

    Article  CAS  PubMed  Google Scholar 

  34. Rhoden EL, Estrada C, Levine L, Morgentaler A . The value of pituitary magnetic resonance imaging in men with hypogonadism. J Urol 2003; 170: 795–798.

    Article  PubMed  Google Scholar 

  35. Buvat J, Lemaire A . Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158: 1764–1767.

    Article  CAS  PubMed  Google Scholar 

  36. Araujo AB, O’Donnell A, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the massachusetts male aging study. J Clin Endocrinol Metab 2004; 89: 5920–5926.

    Article  CAS  PubMed  Google Scholar 

  37. Vermeulen A . Hormonal cut-offs of partial androgen deficiency: a survey of androgen assays. J Endocrinol Invest 2005; 28 (3 Suppl): 28–31.

    CAS  PubMed  Google Scholar 

  38. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H . Utility, limitations, and pitfalls in measuring testosterone: an endocrine society position statement. J Clin Endocrinol Metab 2007; 92: 405–413.

    Article  CAS  PubMed  Google Scholar 

  39. Sikaris K, McLachlan RI, Kazlauskas R, de KD, Holden CA, Handelsman DJ . Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab 2005; 90: 5928–5936.

    Article  CAS  PubMed  Google Scholar 

  40. Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 2003; 49: 1381–1395.

    Article  CAS  PubMed  Google Scholar 

  41. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS . Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2004; 89: 534–543.

    Article  CAS  PubMed  Google Scholar 

  42. Vermeulen A, Verdonck L, Kaufman JM . A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666–3672.

    Article  CAS  PubMed  Google Scholar 

  43. Swerdloff RS, Wang C . Free testosterone measurement by the analog displacement direct assay: old concerns and new evidence. Clin Chem 2008; 54: 458–460.

    Article  CAS  PubMed  Google Scholar 

  44. Rosner W . Errors in the measurement of plasma free testosterone. J Clin Endocrinol Metab 1997; 82: 2014–2015.

    Article  CAS  PubMed  Google Scholar 

  45. Wang C, Plymate S, Nieschlag E, Paulsen CA . Salivary testosterone in men: further evidence of a direct correlation with free serum testosterone. J Clin Endocrinol Metab 1981; 53: 1021–1024.

    Article  CAS  PubMed  Google Scholar 

  46. Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI . Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 2008; 93: 139–146.

    Article  CAS  PubMed  Google Scholar 

  47. Meier C, Nguyen TV, Handelsman DJ, Schindler C, Kushnir MM, Rockwood AL et al. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med 2008; 168: 47–54.

    Article  CAS  PubMed  Google Scholar 

  48. Kenny AM, Prestwood KM, Raisz LG . Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels. Endocr Res 2000; 26: 153–168.

    Article  CAS  PubMed  Google Scholar 

  49. Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 2007; 298: 629–637.

    Article  CAS  PubMed  Google Scholar 

  50. Freitas SS, Barrett-Connor E, Ensrud KE, Fink HA, Bauer DC, Cawthon PM et al. Rate and circumstances of clinical vertebral fractures in older men. Osteoporos Int 2008; 19: 615–623.

    Article  CAS  PubMed  Google Scholar 

  51. Morales A, Buvat J, Gooren LJ, Guay AT, Kaufman JM, Tan HM et al. Endocrine aspects of sexual dysfunction in men. J Sex Med 2004; 1: 69–81.

    Article  CAS  PubMed  Google Scholar 

  52. Black AM, Day AG, Morales A . The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial? BJU Int 2004; 94: 1066–1070.

    Article  PubMed  Google Scholar 

  53. Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J . Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol 2005; 173: 530–532.

    Article  CAS  PubMed  Google Scholar 

  54. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172: 658–663.

    Article  CAS  PubMed  Google Scholar 

  55. Allen NE, Appleby PN, Davey GK, Key TJ . Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men. Cancer Causes Control 2002; 13: 353–363.

    Article  PubMed  Google Scholar 

  56. Kalyani RR, Dobs AS . Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diab Obes 2007; 14: 226–234.

    Article  CAS  Google Scholar 

  57. Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007; 30: 234–238.

    Article  CAS  PubMed  Google Scholar 

  58. Rodriguez A, Muller DC, Metter EJ, Maggio M, Harman SM, Blackman MR et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007; 92: 3568–3572.

    Article  CAS  PubMed  Google Scholar 

  59. Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB . Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 2006; 65: 125–131.

    Article  CAS  Google Scholar 

  60. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH . Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007; 30: 911–917.

    Article  CAS  PubMed  Google Scholar 

  61. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB . Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91: 843–850.

    Article  CAS  PubMed  Google Scholar 

  62. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036–1041.

    Article  CAS  PubMed  Google Scholar 

  63. Kapoor D, Goodwin E, Channer KS, Jones TH . Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899–906.

    Article  CAS  PubMed  Google Scholar 

  64. Corrales JJ, Burgo RM, Garca-Berrocal B, Almeida M, Alberca I, Gonzalez-Buitrago JM et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism 2004; 53: 666–672.

    Article  CAS  PubMed  Google Scholar 

  65. Basu R, Dalla MC, Campioni M, Basu A, Nair KS, Jensen MD et al. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care 2007; 30: 1972–1978.

    Article  CAS  PubMed  Google Scholar 

  66. Roddam AW, Allen NE, Appleby P, Key TJ . Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170–183.

    Article  CAS  PubMed  Google Scholar 

  67. Carpenter WR, Robinson WR, Godley PA . Getting over testosterone: postulating a fresh start for etiologic studies of prostate cancer. J Natl Cancer Inst 2008; 100: 158–159.

    Article  PubMed  Google Scholar 

  68. Fowler Jr JE, Whitmore Jr WF . Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer 1982; 49: 1373–1377.

    Article  PubMed  Google Scholar 

  69. McConnell JD . Prostatic growth: new insights into hormonal regulation. Br J Urol 1995; 76 (Suppl 1): 5–10.

    CAS  PubMed  Google Scholar 

  70. Parekh DJ, Ankerst DP, Higgins BA, Hernandez J, Canby-Hagino E, Brand T et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 2006; 68: 1152–1155.

    Article  PubMed  Google Scholar 

  71. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529–534.

    Article  PubMed  Google Scholar 

  72. Thompson IM, Carroll PR, Carducci MA . Recommendations for defining and treating high risk localized prostate cancer. J Urol 2006; 176 (6 Part 2): S6–S10.

    PubMed  Google Scholar 

  73. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006; 296: 2351–2361.

    Article  CAS  PubMed  Google Scholar 

  74. Meikle AW, Arver S, Dobs AS, Adolfsson J, Sanders SW, Middleton RG et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 1997; 49: 191–196.

    Article  CAS  PubMed  Google Scholar 

  75. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR . Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003; 24: 299–311.

    Article  PubMed  Google Scholar 

  76. Rhoden EL, Morgentaler A . Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482–492.

    Article  CAS  PubMed  Google Scholar 

  77. Agarwal PK, Oefelein MG . Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005; 173: 533–536.

    Article  CAS  PubMed  Google Scholar 

  78. Kaufman JM, Graydon RJ . Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004; 172: 920–922.

    Article  CAS  PubMed  Google Scholar 

  79. Khera M, Lipshultz LI . The role of testosterone replacement therapy following radical prostatectomy. Urol Clin North Am 2007; 34: 549–553, vi.

    Article  PubMed  Google Scholar 

  80. Sarosdy MF . Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007; 109: 536–541.

    Article  CAS  PubMed  Google Scholar 

  81. Nieschlag E, Behre HM . Testosterone: Acion, Deficiency, Substitution, 3rd edn, Cambridge University Press: Cambridge, 2004.

    Book  Google Scholar 

  82. Nieschlag E . Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf) 2006; 65: 275–281.

    Article  CAS  Google Scholar 

  83. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60: 1451–1457.

    Article  PubMed  Google Scholar 

  84. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ . Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005; 14: 2257–2260.

    Article  CAS  PubMed  Google Scholar 

  85. Zitzmann M, Nieschlag E . Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 2007; 92: 3844–3853.

    Article  CAS  PubMed  Google Scholar 

  86. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS . Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006; 27: 57–64.

    Article  CAS  PubMed  Google Scholar 

  87. Hanafy HM . Testosterone therapy and obstructive sleep apnea: is there a real connection? J Sex Med 2007; 4: 1241–1246.

    Article  CAS  PubMed  Google Scholar 

  88. Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I, Rudman D . Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc 1995; 43: 899–901.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The following authors have disclosed their financial support and/or association with organizations that may have a direct financial interest in the material contained in the paper. C Wang has served as a temporary consultant for Indevus, and has received research support from Acrux, Indevus, M et P, Clarus Therapeutics and Besins Healthcare. E Nieschlag and H Behre has received honoraria from various sources for lectures on testosterone, JJ Legros has received a lecture fee from Organon. A Morales has received research support from Solvay. JE Morley has served as a consultant for Solvay and has stock ownership in Mattern Pharmaceuticals. RS Swerdloff has disclosed their financial support as grant recipient, consultant or sponsored speaker in the following companies: Acrux (Consultant, Grant Recipient); Ardana (Consultant, Grant Recipient); Auxillium (Consultant, Grant Recipient, Speaker); Clarus (Consultant, Grant Recipient); Glaxo SmithKline (Consultant, Grant Recipient); Indevus (Consultant, Grant Recipient); Organon (Grant recipient); Pierre Fabre (Consultant); Solvay Pharmaceuticals, Inc Company (Consultant, Grant Recipient, Speaker) and Repros (Consultant, Grant Recipient). RS Swerdloff is not a stockholder or owner of any of these companies.

The following authors: W Hellstrom, L Gooren, J Kaufman, B Lunenfeld, C Schulman, IM Thompson, W Weidner and FCW Wu have certified that they have no financial disclosures to make regarding their participation in the data analysis, writing and approval of this paper.

Author information

Authors and Affiliations

  1. Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center and Los Angeles BioMedical Research Institute, Torrance, CA, USA

    C Wang & R Swerdloff

  2. Centre for Reproductive Medicine and Andrology, University of Muenster, Muenster, Germany

    E Nieschlag

  3. Center for Reproductive Medicine and Andrology, University Hospital Halle, Martin-Luther-University Halle-Wittenberg, Halle, Germany

    H M Behre

  4. Department of Urology, Tulane University, New Orleans, LA, USA

    W J Hellstrom

  5. Department of Endocrinology, VU University Medical Center, Amsterdam, The Netherlands

    L J Gooren

  6. Department of Endocrinology, Academish Ziekenhuis, Gent, Belgium

    J M Kaufman

  7. Centre Hospitalier Universitaire, Liège, Belgium

    J-J Legros

  8. Faculty Life Science, Bar-Ilan University, Israel

    B Lunenfeld

  9. Centre for Applied Urological Research, Queen's University, Kingston, Ontario, Canada

    A Morales

  10. Division of Geriatric Medicine, St Louis University, and GRECC, St Louis VA Medical Center, St Louis, MO, USA

    J E Morley

  11. Department of Urology, Erasme Hospital, University Clinics Brussels, Brussels, Belgium

    C Schulman

  12. Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    I M Thompson

  13. Department of Urology and Pediatric Urology, University Hospitals, Justus-Liebig-University, Giessen, Germany

    W Weidner

  14. Department of Endocrinology, University of Manchester, Manchester Royal Infirmary, Manchester, UK

    F C W Wu

Authors
  1. C Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Nieschlag
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Swerdloff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H M Behre
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W J Hellstrom
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L J Gooren
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J M Kaufman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J-J Legros
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B Lunenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Morales
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J E Morley
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C Schulman
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. I M Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. W Weidner
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. F C W Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Wang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, C., Nieschlag, E., Swerdloff, R. et al. ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res 21, 1–8 (2009). https://doi.org/10.1038/ijir.2008.41

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2008.41

Keywords

This article is cited by

Search

Advanced search

Quick links